AbCellera

AbCellera Biologics Inc. is a biotechnology company based in Vancouver, British Columbia, founded in 2012 as a spin-out from the University of British Columbia. The company specializes in antibody discovery and development, utilizing a proprietary technology platform that incorporates microfluidics and single-cell analysis. This innovative approach allows AbCellera to rapidly identify therapeutic antibodies from natural immune responses. The company offers a high-throughput antibody discovery platform that screens millions of immune cells to quickly find potent antibodies, enabling the development of medical countermeasures in about 60 days. AbCellera provides comprehensive services from discovery through clinical manufacturing, focusing on developing first-in-class and best-in-class antibody medicines. It has collaborated with major pharmaceutical companies and organizations, completing over 100 therapeutic antibody discovery programs across various medical fields, including infectious diseases, oncology, and autoimmunity. AbCellera is dedicated to creating medicines that improve lives and aims to transform antibody drug development through technological innovation.